Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.

Abstract

OBJECTIVES:

To examine whether baseline anti-cyclic citrullinated peptide-2 (CCP2) antibody status and concentration correlated with clinical outcomes in patients treated with abatacept or adalimumab on background methotrexate (MTX) in the 2-year AMPLE (Abatacept versus adaliMumab comParison in bioLogic-naïvE rheumatoid arthritis subjects with background MTX) study.

METHODS:

In this exploratory analysis, anti-CCP2 antibody concentration was measured at baseline, and antibody-positive patients were divided into equal quartiles, Q1-Q4, representing increasing antibody concentrations. Clinical outcomes analysed by baseline anti-CCP2 status and quartile included change from baseline in disease activity and disability and remission rates.

RESULTS:

Baseline characteristics were generally comparable across quartiles and treatment groups. In both treatment groups, anti-CCP2 antibody-negative patients responded less well than antibody-positive patients. At year 2, improvements in disease activity and disability and remission rates were similar across Q1-Q3, but were numerically higher in Q4 in the abatacept group; in contrast, treatment effects were similar across all quartiles in the adalimumab group.

CONCLUSIONS:

In AMPLE, baseline anti-CCP2 positivity was associated with a better response for abatacept and adalimumab. Patients with the highest baseline anti-CCP2 antibody concentrations had better clinical response with abatacept than patients with lower concentrations, an association that was not observed with adalimumab.

TRIAL REGISTRATION NUMBER:

NCT00929864.

• Authors: Jeremy Sokolove, Michael Schiff, Roy Fleischmann, Michael E Weinblatt, Sean E Connolly, Alyssa Johnsen, Jin Zhu, Michael A Maldonado, Salil Patel, William H Robinson
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 75 Issue 4 Pg. 709-14 (Apr 2016) ISSN: 1468-2060 [Electronic] England
• PMID: 26359449 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Chemical References

• Antirheumatic Agents
• Autoantibodies
• Immunoglobulin G
• Peptides, Cyclic
• cyclic citrullinated peptide
• Abatacept
• Adalimumab
• Methotrexate

Topics

• Abatacept (therapeutic use)
• Adalimumab (therapeutic use)
• Adult
• Aged
• Aged, 80 and over
• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (drug therapy, immunology)
• Autoantibodies (immunology)
• Drug Therapy, Combination
• Female
• Humans
• Immunoglobulin G (immunology)
• Injections, Subcutaneous
• Male
• Methotrexate (therapeutic use)
• Middle Aged
• Peptides, Cyclic (immunology)
• Prognosis
• Single-Blind Method
• Treatment Outcome
• Young Adult